GSK PLC GSK shares slipped 2.45% to £15.36 Friday, on what proved to be an all-around grim trading session for the stock ...
The GSK share price has had a rotten few years and now it's heading south yet again. Investor Harvey Jones continues to hang ...
GSK(LSE:GSK) is navigating a dynamic environment marked by both opportunities and challenges. Recent highlights include a ...
GSK has revised its annual vaccine sales forecast following new guidance on RSV from the CDC. But new evidence offers new ...
GSK's new long-acting drug candidate for severe asthma, depemokimab, reduced the rate of severe attacks by 54% in a pair of ...
British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot ...
GSK touts co-administration data for RSV, shingles vaccines as narrowed CDC guidance threatens sales
In the study, co-administration of GSK's RSV vaccine Arexvy and shingles shot Shingrix elicited non-inferior immune responses ...
After an initial defeat against the biggest barrier to mRNA flu vaccines—namely, B strains of influenza—GSK has returned with a reformulated candidate that has ...
A targeted immunotherapy being developed by iTeos Therapeutics and GSK, it was reported at #ESMO, delivered promising ...
The value of your investments can go ... Zantac was first linked to cancer in 2019. GSK had previously settled various lawsuits. However, on 31 May a US court in Delaware ruled that 70,000+ new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback